Daprodustat

Daprodustat

Clinical data
Trade names	Duvroq, Jesduvroq
Other names	GSK1278863
License data	US DailyMed: Daprodustat
Routes of administration	By mouth
Drug class	Hypoxia-inducible factor prolyl hydroxylase inhibitor
ATC code	B03XA07 (WHO)
Legal status
Legal status	US: ℞-only In general: ℞ (Prescription only)
Identifiers
IUPAC name 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid
CAS Number	960539-70-2
PubChem CID	91617630
DrugBank	DB11682
ChemSpider	33427356
UNII	JVR38ZM64B
KEGG	D10874
ChEMBL	ChEMBL3544988
ECHA InfoCard	100.219.426
Chemical and physical data
Formula	C19H27N3O6
Molar mass	393.440 g·mol−1
3D model (JSmol)	Interactive image
SMILES C3CCCCC3n(c(=O)c1C(=O)NCC(=O)O)c(=O)n(c1O)C2CCCCC2
InChI InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,26H,1-11H2,(H,20,25)(H,23,24) Key:NVTKJBXOBFRPLQ-UHFFFAOYSA-N

Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth.

The most common side effects include high blood pressure, thrombotic vascular events, abdominal pain, dizziness and allergic reactions. 

Daprodustat was approved for medical use in Japan in June 2020, and in the United States in February 2023. It is the first oral treatment for anemia caused by chronic kidney disease for adults.

Medical uses

Daprodustat is indicated for the treatment of anemia due to chronic kidney disease.

History

Daprodustat increases erythropoietin levels. The effectiveness of daprodustat was established in a randomized study of 2,964 adult participants receiving dialysis. In this study, participants received either oral daprodustat or injected recombinant human erythropoietin (a standard of care treatment for people with anemia due to chronic kidney disease). Daprodustat raised and maintained the hemoglobin (the protein in red blood cells that carries oxygen and is a common measure of anemia) within the target range of 10-11 grams/deciliter, similar to that of the recombinant human erythropoietin. The US Food and Drug Administration (FDA) granted the approval of Jesduvroq to GlaxoSmithKline LLC.

Society and culture

Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs.

Research

Daprodustat is in phase III clinical trials for the treatment of anemia caused by chronic kidney disease.

External links

• Clinical trial number NCT02879305 for "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)" at ClinicalTrials.gov